StreetAlpha
13F holdings · Q3 2026

Fairmount Funds Management

West Conshohocken, PA · files as Fairmount Funds Management LLC
Know the moment Fairmount Funds Management filesYou follow Fairmount Funds Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1802528

Fairmount Funds Management reported 12 stocks worth $1.6B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ORKA (19.4%), KRSA (18.3%) and DNTH (14.0%). Compared with Q2 2026, the fund opened new positions in KRSA and DMRA and added to ZBIO and CBIO.

Latest filing: what Fairmount Funds Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
2 new2 added0 trimmed2 sold outBought about $490M · sold about $266M
New 2
Added 2
Trimmed 0

None

Sold out 2
  • Galecto Inc$227M
  • Apogee Therapeutic$39.6M

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$1.6B+5.4% vs last quarter
Stocks held122 new · 2 sold out
Top 5 weight74.3%very concentrated
Turnover47%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
ORKA
Oruka Therapeutics Inc
$309M19.4%3.7MNo change8 of 8
2
KRSA
Korsana Biosciences Inc
$291M18.3%9.1MNew position1 of 8
3
DNTH
Dianthus Therapeutics Inc
$223M14.0%2.5MNo change8 of 8
4
DMRA
Damora Therapeutics Inc
$185M11.6%8.7MNew position1 of 8
5
COGT
Cogent Biosciences Inc
$176M11.1%5.5MNo change8 of 8
6
VRDN
Viridian Therapeutics Inc
$105M6.6%5.1MNo change8 of 8
7
ELVN
Enliven Therapeutics Inc
$85.1M5.3%1.9MNo change8 of 8
8
JBIO
Jade Biosciences Inc
$64M4.0%4.6MNo change6 of 8
9
ZBIO
Zenas Biopharma Inc
$64M4.0%2.4M+12K (+1%)8 of 8
10
CBIO
Crescent Biopharma Inc.
$52.5M3.3%3.6M+853K (+31%)6 of 8
🔒 2 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
GALECTO INC
$227M8.7M
APOGEE THERAPEUTICS INC
$39.6M299K

Reported value

last 8 quarters
$1BQ4 '24
$645MQ1 '25
$772MQ2 '25
$1.1BQ3 '25
$1.3BQ4 '25
$1.4BQ1 '26
$1.5BQ2 '26
$1.6BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Fairmount Funds Management 13F FAQ

What does Fairmount Funds Management own?

Fairmount Funds Management reported 12 stocks worth $1.6B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ORKA (19.4%), KRSA (18.3%) and DNTH (14.0%). The table above lists every position in the filing (the top 10 without an account).

What did Fairmount Funds Management buy and sell in Q3 2026?

Compared with Q2 2026: 2 new positions, 2 added to, 0 trimmed and 2 sold out. New positions include KRSA and DMRA.

When will Fairmount Funds Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Fairmount Funds Management's portfolio worth?

The Q3 2026 filing reports $1.6B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.